Osmotica Pharmaceuticals (NASDAQ:OSMT) Coverage Initiated at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald began coverage on shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) in a report issued on Friday, Analyst Ratings Network reports. The brokerage set an “overweight” rating and a $6.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 108.33% from the stock’s current price.

Separately, Zacks Investment Research upgraded Osmotica Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 14th.

Shares of OSMT stock opened at $2.88 on Friday. The firm has a market capitalization of $180.24 million, a price-to-earnings ratio of -1.99 and a beta of 2.69. The business has a fifty day moving average of $3.47 and a 200 day moving average of $3.27. Osmotica Pharmaceuticals has a 1 year low of $2.70 and a 1 year high of $6.49.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Monday, August 16th. The company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.14). The company had revenue of $11.51 million for the quarter, compared to analysts’ expectations of $34.50 million. Osmotica Pharmaceuticals had a negative net margin of 71.48% and a negative return on equity of 43.86%. Equities analysts predict that Osmotica Pharmaceuticals will post -0.89 earnings per share for the current year.

Several large investors have recently bought and sold shares of OSMT. Morgan Stanley grew its position in shares of Osmotica Pharmaceuticals by 55.8% during the 1st quarter. Morgan Stanley now owns 1,930,781 shares of the company’s stock valued at $6,295,000 after acquiring an additional 691,486 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Osmotica Pharmaceuticals during the 1st quarter valued at about $542,000. Millennium Management LLC acquired a new stake in shares of Osmotica Pharmaceuticals during the 2nd quarter valued at about $482,000. Ergoteles LLC acquired a new stake in Osmotica Pharmaceuticals in the 2nd quarter worth about $172,000. Finally, GSA Capital Partners LLP acquired a new stake in Osmotica Pharmaceuticals in the 1st quarter worth about $125,000. Hedge funds and other institutional investors own 7.71% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women’s health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs.

Read More: Fibonacci Channel

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.